➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
AstraZeneca
McKesson
Johnson and Johnson
McKinsey

Last Updated: January 21, 2021

DrugPatentWatch Database Preview

Bausch Company Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Bausch
International Patents:415
US Patents:62
Tradenames:122
Ingredients:99
NDAs:140
Patent Litigation for Bausch: See patent lawsuits for Bausch

Drugs and US Patents for Bausch

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch JUBLIA efinaconazole SOLUTION;TOPICAL 203567-001 Jun 6, 2014 RX Yes Yes 7,214,506   Start Trial   Start Trial
Bausch And Lomb ALBUTEROL SULFATE albuterol sulfate SOLUTION;INHALATION 075050-001 Jun 18, 1998 DISCN No No   Start Trial   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-002 Feb 6, 2003 AB RX Yes No 6,923,984   Start Trial Y   Start Trial
Bausch MINOCIN minocycline hydrochloride CAPSULE;ORAL 050649-003 Feb 12, 2001 DISCN Yes No   Start Trial   Start Trial
Bausch ISORDIL isosorbide dinitrate TABLET;ORAL 012093-001 Jul 29, 1988 AB RX Yes Yes   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Bausch

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-006 Feb 6, 2003 5,529,791   Start Trial
Bausch CARDIZEM LA diltiazem hydrochloride TABLET, EXTENDED RELEASE;ORAL 021392-005 Feb 6, 2003 7,108,866   Start Trial
Bausch VASOTEC enalapril maleate TABLET;ORAL 018998-003 Dec 24, 1985 4,374,829*PED   Start Trial
Bausch VASOTEC enalapril maleate TABLET;ORAL 018998-002 Dec 24, 1985 4,374,829*PED   Start Trial
Bausch ZELAPAR selegiline hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 021479-001 Jun 14, 2006 5,648,093   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BAUSCH drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Capsules 75 mg ➤ Subscribe 2011-06-06
➤ Subscribe Gel 0.77% ➤ Subscribe 2006-05-10
➤ Subscribe Extended-release Tablets 120 mg, 180 mg, 240 mg, 300 mg and 360 mg ➤ Subscribe 2005-08-30
➤ Subscribe Ophthalmic Solution 0.5% ➤ Subscribe 2012-10-19
➤ Subscribe Cream 5% ➤ Subscribe 2006-10-17
➤ Subscribe Ophthalmic Solution 1.5% ➤ Subscribe 2013-09-09
➤ Subscribe Cream 3.75% ➤ Subscribe 2012-08-08
➤ Subscribe Rectal Gel 2.5 mg/0.5 mL, 5 mg/mL, 10 mg/2 mL, 15 mg/3 mL and 20 mg/4 mL ➤ Subscribe 2004-03-23
➤ Subscribe Rectal Gel 5 mg/mL, 2mL pre-filled syringe ➤ Subscribe 2008-12-23
➤ Subscribe Gel 1.2%/3.75% ➤ Subscribe 2015-09-30
➤ Subscribe Vaginal Gel 0.75% ➤ Subscribe 2004-09-02
➤ Subscribe Topical Solution 10% ➤ Subscribe 2018-06-06
➤ Subscribe Extended-release Tablets 420 mg ➤ Subscribe 2005-04-25
➤ Subscribe Ophthalmic Solution 0.07% ➤ Subscribe 2013-07-26
➤ Subscribe Lotion 0.1% ➤ Subscribe 2016-08-31
➤ Subscribe Cream 2.5% ➤ Subscribe 2014-06-17
➤ Subscribe Rectal Gel 5 mg/mL, 4mL pre-filled syringe ➤ Subscribe 2008-12-08
➤ Subscribe Gel 1.2%/2.5% ➤ Subscribe 2012-12-20
Premature patent expirations for BAUSCH

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
  Start Trial   Start Trial

Supplementary Protection Certificates for Bausch Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1499331 SPC/GB13/034 United Kingdom   Start Trial PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
2673237 LUC00111 Luxembourg   Start Trial PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1173 20180326
0284288 12/1998 Austria   Start Trial PRODUCT NAME: TAZAROTENE; NAT. REGISTRATION NO/DATE: 1-22102, 1-22103 19970918; FIRST REGISTRATION: DE 37393.00.00, 37393.01.00 19961203
1874117 2014/032 Ireland   Start Trial PRODUCT NAME: DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, INCLUDING DOLUTEGRAVIR SODIUM; REGISTRATION NO/DATE: EU/1/13/892/001-002 20140121
2712622 LUC00015 Luxembourg   Start Trial PRODUCT NAME: DESMOPRESSINE OU UN DE SES SELS D'ACETATE; AUTHORISATION NUMBER AND DATE: 497271; 497280 20161101
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Moodys
Boehringer Ingelheim
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.